|
|
Competition on the Future Leukemia MarketsPublished by: BioSeeker Group AB Published: Oct. 26, 2004 Table of ContentsBSG General Working Model & Methodology Acute Lymphoblastic Leukemia & Related Competition Introduction & Current Treatment Options Box 1. Major treatment regimes Next-generation nucleoside antimetabolite Slow progress for DNA topoisomerase II inhibitor Novel Ribonucleotide Reductase Inhibitor Moves Clinical Table 1. Near Term Progress. Old ribonucleotide reductase inhibitor discontinued Fast track status on second-generation immunomodulator Table 2. Near Term Progress Chronic Lymphocytic Leukemia & Related Competition Introduction & Current Treatment Options Box 2. CLL staging system Box 3 - Updated REAL/WHO Classification for B-Cell Neoplasms Blockbuster heading for new markets Table 3. Near Term Progress Questioned sincerity and reliability by the FDA Table 4. Near Term Progress Competitive studies Box. 4. Large Campath Study Evaluate the Efficacy and Safety of Front-Line Therapy with Alemtuzumab vs. Chlorambucil. Table 5. Near Term Progress Clinical studies initiated for apoptotic drug Discontinuation due to toxicity Table 6. Near Term Progress Phase II data on apoptosis inducer Table 7. Near Term Progress Acute Myeloid Leukemia & Related Competition Introduction & Current Treatment Options Box 5. The general structure for treatment of AML Continuing efforts on Mylotarg Table 8. Near Term Progress A sub-population of the patients are cured Table 9. Near Term Progress Initiation of Phase III Flt3 Ligand Table 10. Near Term Progress Moving up to phase II Targeting intracelluar kinases Table 11. Near Term Progress Table 12 Near Term Progress Is VEGF receptor inhibition the right target? Table 13. Near Term Progress Table 14 Near Term Progress Several DNA targeting drugs in development Table 15. Near Term Progress Table 16 Near Term Progress Cancer Vaccine Struggle Additional Mab therapy for the treatment of AML? Multidrug resistance inhibitor Combination treatment superior Chronic Myelogenous Leukemia & Related Competition Introduction & Current Treatment Options Box 5. CML R&D Sixty studies presented on Gleevec Table 17. Near Term Progress. The Interferons Table 18. Clinical studies including Interferon for the treatment of leukemia. Farnesyl transferase inhibitors for the treatment of leukemia Table 19. Near Term Progress Overcoming Gleevec resistance? Table 20. Near Term Progress Additional strategies Another blockbuster seeking new markets Table 21. Near Term Progress Personalized Vaccine MDR inhibitor Inducing apoptosis Disclaimer Liability Completeness AbstractLeukemia includes a broad variety of histological separate disorders. These make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.This has now clearly changed with the launch of Novartis' second-line therapy Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 47 percent to $757 million in the first half 2004. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Additional progress in disease molecular pathology, and research into the possible significance of innovative predictive markers will offer physicians with supplementary information with which to compose future treatment strategies. To enable customers to keep update their knowledge status at the same time receive a basic foundation, this report "Competition on the Future Leukemia Markets" describes and analyzes the latest year of progress in four different market segments; CLL, CML ALL and AML. This report provides one of the most comprehensive coverages of the R&D trends to set the future leukemia marketplace. BioSeeker Group presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions of drugs and targets. It identifies 35 drug candidates in phase II or III stage of development. Among these drugs can clearly be seen substantial progress while others have failed. There will soon be a harder competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies. The information structure in this cancer highlight report will as well provide an easy reading format to track B2B collaborations and industry academic relationships. Therapeutic candidates included in this analysis: AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999
|
|
|||
|
About MarketResearch.com
|
||||